格隆汇1月30日丨赛诺医疗(688108.SH)公布2025年度业绩预增公告，报告期内，预计实现归属于上市公 司股东的净利润与上年同期相比将大幅增长：预计实现归属于上市公司股东的净利润为4,300万元至 5,000万元，较上年同期增加4,150万元至4,850万元，同比增长2,767%至3,233%。报告期内，预计实现归 属于上市公司股东的扣除非经常性损益后的净利润实现扭亏为盈：预计实现归属于上市公司股东的扣除 非经常性损益后的净利润为3,000万元至3,580万元，较上年同期增加4,752万元至5,332万元，同比增长 271%至304%。 报告期内，公司球囊和支架产品的销量同比大幅增长，产品的规模效应进一步显现，从而带动单位产品 成本同比大幅下降；然而单位成本下降对营业成本的节约效应略小于销量增长带来的成本增加影响，因 此预计营业成本同比小幅增长。 ...

截至发稿，胡崇海累计任职时间4年33天，现任基金资产总规模136.84亿元，任职期间最佳基金回报 90.54%， 任职期间最差基金回报0.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月15日，赛诺医疗跌5%，截至发稿，报22.99元/股，成交4.37亿元，换手率4.45%，总市值95.65亿元。 从基金十大重仓股角度 数据显示，国泰海通资管旗下1只基金重仓赛诺医疗。国泰海通量化选股混合发起A（016466）三季度 持有股数44.43万股，占基金净值比例为0.89%，位居第一大重仓股。根据测算，今日浮亏损失约53.76 万元。 国泰海通量化选股混合发起A（016466）成立日期2022年8月18日，最新规模5.99亿。今年以来收益 8.38%，同类排名1383/8840；近一年收益47.95%，同类排名2150/8094；成立以来收益60.05%。 国泰海通量化选股混合发起A（016466）基金经理为胡崇海。 资料显示，赛诺医疗科学技术股 ...

Group 1 - The core viewpoint of the news is that Sino Medical has experienced significant stock price fluctuations and trading activity, with a year-to-date increase of 109.63% and a recent decline of 2.06% on December 29 [1] - As of December 29, Sino Medical's stock price is reported at 20.46 yuan per share, with a total market capitalization of 8.512 billion yuan [1] - The company has seen a net outflow of main funds amounting to 1.7348 million yuan, with large orders showing a buy of 82.0063 million yuan and a sell of 78.5717 million yuan [1] Group 2 - Sino Medical, established on September 21, 2007, specializes in high-end interventional medical devices, with its main revenue sources being stents (59.76%), balloons (32.68%), and others (7.56%) [2] - The company reported a revenue of 364 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 14.24%, and a net profit of 21.118 million yuan, which is a significant increase of 293.46% [2] - As of September 30, the number of shareholders increased by 164.74% to 29,400, while the average circulating shares per person decreased by 62.23% to 14,170 shares [2] Group 3 - Sino Medical has cumulatively distributed 41 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]

12月25日，赛诺医疗涨5.12%，截至发稿，报18.69元/股，成交2.13亿元，换手率2.83%，总市值77.76亿 元。 国泰海通量化选股混合发起A（016466）基金经理为胡崇海。 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦A区3 层，成立日期2007年9月21日，上市日期2019年10月30日，公司主营业务涉及高端介入医疗器械研发、 生产、销售,产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。主营业务收入构成 为：支架59.76%，球囊32.68%，其他7.56%。 从基金十大重仓股角度 数据显示，国泰海通资管旗下1只基金重仓赛诺医疗。国泰海通量化选股混合发起A（016466）三季度 持有股数44.43万股，占基金净值比例为0.89%，位居第一大重仓股。根据测算，今日浮盈赚取约40.43 万元。 国泰海通量化选股混合发起A（016466）成立日期2022年8月18日，最新规模5.99亿。今年以来收益 33.18%，同类排名2673/8087；近一年收益30.85%，同类排名2722/8071；成立以来收益47.24%。 截至发稿，胡崇海累计任职时 ...

12月19日，赛诺医疗涨5.09%，截至发稿，报18.39元/股，成交1.69亿元，换手率2.25%，总市值76.51亿 元。 国泰海通量化选股混合发起A（016466）基金经理为胡崇海。 截至发稿，胡崇海累计任职时间4年6天，现任基金资产总规模136.84亿元，任职期间最佳基金回报 68.39%， 任职期间最差基金回报-0.17%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦A区3 层，成立日期2007年9月21日，上市日期2019年10月30日，公司主营业务涉及高端介入医疗器械研发、 生产、销售,产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。主营业务收入构成 为：支架59.76%，球囊32.68%，其他7.56%。 从基金十大重仓股角度 数据显示，国泰海通资管旗下1只基金重仓赛诺医疗。国泰海通量化选股混合发起A（016466）三季度 持有股数44 ...

12月19日，赛诺医疗盘中上涨2.00%，截至09:54，报17.85元/股，成交3045.69万元，换手率0.41%，总 市值74.26亿元。 赛诺医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、小盘、QFII 持股、融资融券、专精特新等。 截至9月30日，赛诺医疗股东户数2.94万，较上期增加164.74%；人均流通股14170股，较上期减少 62.23%。2025年1月-9月，赛诺医疗实现营业收入3.64亿元，同比增长14.24%；归母净利润2111.80万 元，同比增长293.46%。 分红方面，赛诺医疗A股上市后累计派现4100.00万元。近三年，累计派现0.00元。 责任编辑：小浪快报 资金流向方面，主力资金净流入5.67万元，大单买入402.49万元，占比13.22%，卖出396.82万元，占比 13.03%。 赛诺医疗今年以来股价涨82.89%，近5个交易日跌0.22%，近20日跌0.56%，近60日跌39.08%。 今年以来赛诺医疗已经7次登上龙虎榜，最近一次登上龙虎榜为10月29日，当日龙虎榜净买入-5123.31 万元；买入总计2.04亿元 ，占总成交额比1 ...

Core Viewpoint - The demand for cerebrovascular interventional devices in China is increasing due to the rising incidence of cerebrovascular diseases, which are among the top three causes of death in the country, with stroke being the leading cause [1][10]. Industry Definition and Classification - Cerebrovascular diseases are conditions affecting blood vessels in the brain, primarily including ischemic and hemorrhagic strokes. Cerebrovascular interventional surgery involves minimally invasive techniques for diagnosing and treating these conditions [2]. - Cerebrovascular interventional devices include medical consumables required for these surgeries, such as embolization coils, thrombectomy stents, and aspiration catheters [2]. Industry Characteristics - The cerebrovascular interventional device industry is characterized by high technical barriers, continuous technological innovation, and favorable industry policies [4]. Current Industry Status Global Market - The global market for cerebrovascular interventional devices is projected to reach USD 3.292 billion in 2024, with North America accounting for 43.04% of the market, Europe 26.56%, and Asia-Pacific 25.27%. The market is expected to grow to USD 3.974 billion by 2025 [7]. Chinese Market - In China, the market for cerebrovascular interventional devices is expected to reach CNY 3.504 billion in 2024, with specific segments such as intracranial thrombectomy stents at CNY 1.584 billion and aspiration catheters at CNY 0.272 billion. By 2025, the market is projected to grow to CNY 4.879 billion [10][13]. Industry Supply Chain - The upstream of the cerebrovascular interventional device industry consists of raw material suppliers, including tubing and alloy materials. The midstream includes manufacturers like Medtronic and Johnson & Johnson, while the downstream consists of distribution channels and end customers, primarily medical institutions [15].

Core Viewpoint - The demand for neurointerventional medical devices in China is increasing due to the rising incidence of cerebrovascular diseases, with stroke being the leading cause of death among Chinese residents. The market for neurointerventional consumables is projected to grow significantly in the coming years [1][5]. Industry Definition and Classification - Neurointerventional devices are medical consumables required for neurointerventional surgeries, primarily used to diagnose and treat cerebrovascular diseases through minimally invasive techniques [2][3]. Industry Development Status - The global market for neurointerventional consumables is expected to reach $3.292 billion in 2024, with North America holding a 43.04% market share. The Chinese market for these consumables is projected to grow from 3.504 billion yuan in 2024 to 4.879 billion yuan in 2025 [5][6]. Industry Chain - The upstream of the neurointerventional device industry consists of raw material suppliers, while the midstream includes manufacturers like Medtronic and Johnson & Johnson. The downstream consists of medical institutions that utilize these devices [7]. Industry Development History - The neurointerventional device industry in China has evolved through three stages: the embryonic stage (1980-1999), the initiation stage (2000-2010), and the rapid development stage (2011-present) [8]. Competitive Landscape - The market is primarily dominated by multinational companies such as Medtronic and Johnson & Johnson, while domestic companies like Guichuang Tongqiao and Micron Brain Science are gaining ground through competitive pricing and localized channels [9][10]. Key Enterprises - The leading companies in the Chinese neurointerventional market include Medtronic, Stryker, and Johnson & Johnson, with a significant presence of domestic players like Guichuang Tongqiao and Micron Brain Science [10][11]. Technological Breakthroughs - Domestic companies are achieving technological advancements in core products, allowing them to compete more effectively with international standards while benefiting from cost advantages [12]. Application Scenario Expansion - The application of new technologies such as AI-assisted navigation systems and biodegradable materials is expected to enhance the efficiency and scope of neurointerventional procedures, supported by favorable government policies [13].

Group 1 - The article highlights a series of corruption cases involving pharmaceutical companies and agents bribing hospital personnel, with the National Healthcare Security Administration (NHSA) stating that such bribery disrupts normal medical practices and shifts sales from clinical value to high rebates and kickbacks [2][6] - Multiple companies, including Medtronic and A-share listed companies like Qianhong Pharmaceutical and Dezhan Health, have been named in recent court rulings related to these corruption cases [2][5] - Specific cases include Medtronic's agents bribing hospital officials with kickbacks of 5,000 yuan per stent and varying amounts for balloons, leading to a total bribe exceeding 14 million yuan [3][4] Group 2 - The case involving Qianhong Pharmaceutical and Dezhan Health reveals that from January 2013 to May 2019, a hospital's pharmacy director received over 116,000 yuan in bribes from various pharmaceutical representatives, including 4,100 yuan from Qianhong Pharmaceutical [5] - The NHSA has established a credit evaluation system for pricing and procurement to address the inflated prices revealed by these cases, aiming to protect patients and healthcare funds [6]

Core Insights - Government subsidies are a common and significant financial indicator for A-share listed companies, with a total of 890 companies receiving subsidies amounting to 3.354 billion yuan, covering 31 industries as of the first half of this year [1][12][14] Summary by Sections Government Subsidy Overview - Government subsidies can either serve as "lifelines" for companies to turn losses into profits or as "cover-ups" for operational difficulties [1] - The total amount of government subsidies received by listed companies reached 3.354 billion yuan, with 890 companies benefiting [1][12] Companies with Significant Subsidies - Eight companies received over 100 million yuan in subsidies, including China Petroleum (360 million yuan), Conch Cement (196.96 million yuan), and Gujia Home (139.35 million yuan) [3][4] - China Petroleum leads with a subsidy amount that is 1.8 times the average of the other seven companies, reflecting its status as a central enterprise in the energy sector [5] Industry Impact - The companies receiving substantial subsidies are primarily industry leaders or regional pillars, aligning with government goals to stabilize supply chains and promote industrial upgrades [4][9] - The medical device company Sainuo Medical received 2 million yuan in subsidies, which accounted for 133.53% of its net profit, indicating a heavy reliance on government support [6][8] Sector Analysis - The pharmaceutical and biological sector has the highest number of companies receiving subsidies, totaling 77, followed by machinery equipment (74) and basic chemicals (71) [13] - Traditional industries like textiles and retail have fewer companies receiving subsidies, indicating a policy focus on high-value-added and strategic emerging industries [14] ST Companies and Subsidy Reliance - Among 25 ST companies, only ST Juewei remains profitable, while others are in loss, highlighting the critical role of subsidies in avoiding delisting [10][11] - ST Yingfeitou received the highest subsidy of 6.9004 million yuan, while ST Saiwei received the lowest at 0.01 million yuan [11][10]